Lentivirus-AIMP2-DX2 shRNA suppresses cell proliferation by regulating akt1 signaling pathway in the lungs of AIMP2 Mice

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 26, Issue 3, 2013, Pages 165-173

  Hwang, Soon Kyung ^a,b   Chang, Seung Hee ^a   Minai Tehrani, Arash ^a   Kim, Yeon Soo ^c   Cho, Myung Haing ^a,d  

^a Seoul National University   (South Korea)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Inje University   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

aerosol gene delivery; Akt1 signaling pathway; angiogenesis; shRNA AIMP2 DX2

Indexed keywords

AKT1 PROTEIN; AMINO ACID TRANSFER RNA LIGASE; AMINO ACID TRANSFER RNA LIGASE INTERACTING MULTIFUNCTIONAL PROTEIN; ANTINEOPLASTIC AGENT; DX2 PROTEIN; LENTIVIRUS VECTOR; PROTEIN KINASE B; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; EXON; GENE TARGETING; LUNG CARCINOGENESIS; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM;

ADMINISTRATION, INHALATION; AEROSOLS; AMINO ACYL-TRNA SYNTHETASES; ANIMALS; CELL PROLIFERATION; DISEASE PROGRESSION; GENE KNOCKDOWN TECHNIQUES; GENE TRANSFER TECHNIQUES; LENTIVIRUS; LUNG; LUNG NEOPLASMS; MALE; MICE; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84878415381     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2011.0959     Document Type: Article

References (31)

1. Dailey LA, Kleemann E, Merdan T, Petersen H, Schmehl T, Gessler T, Hanze J, Seeger W, and Kissel T: Modified polyethylenimines as non viral gene delivery systems for aerosol therapy: effects of nebulization on cellular uptake and transfection efficiency. J Control Release. 2004;100:425-436.
2. Ferrari S, Geddes DM, and Alton EW: Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis. Adv Drug Deliv Rev. 2002;54:1373-1393.
3. Merdan T, Kopecek J, and Kissel T: Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev. 2002;54:715-758.
4. Goula D, Becker N, Lemkine GF, Normandie P, Rodrigues J, Mantero S, Levi G, and Demeneix BA: Rapid crossing of the pulmonary endothelial barrier by polyethylenimine/DNA complexes. Gene Ther. 2000;7:499-504.
5. Densmore CL: Advances in noninvasive pulmonary gene therapy. Curr Drug Deliv. 2006;3:55-63.
6. Yang Y, Nunes FA, and Berencsi K: Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA. 1994;91:4407-4411.
7. Miller D, Adam MA, and Miller AD: Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol. 1992;10:4239-4242.
8. Kafri T, Blomer U, and Peterson DA: Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet. 1997;17: 314-317.
9. Hannon GJ, and Rossi JJ: Unlocking the potential of the human genome with RNA interference. Nature. 2004;431: 371-378.
10. Tomari Y, and Zamore PD: Perspective: machines for RNAi. Genes Dev. 2005;19:517-529.
11. Kootstra NA, and Verma IM: Gene therapy with viral vectors. Annu Rev Pharmacol Toxicol. 2003;43:413-439.
12. Luigi N, Ulrike B, Fred HG, Didier T, and Inder MV: Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA. 1996;93:11382-11388.
13. Lee SW, Cho BH, Park SG, and Kim S: Aminoacyl-tRNA synthetase complexes: beyond translation. J Cell Sci. 2004; 117:3725-3734.
14. Park SG, Ewalt KL, and Kim S: Functional expansion of aminoacyl-tRNA synthetases and their interacting factors: new perspectives on housekeepers. Trends Biochem Sci. 2005;30:569-574.
15. Lee YN, Nechushtan H, Figov N, and Razin E: The function of lysyl-tRNA synthetase and Ap4A as signaling regulators of MITF activity in FceRI-activated mast cells. Immunity. 2004;20:145-151.
16. Park H, Park SG, Lee JW, Kim T, Kim G, Ko YG, and Kim S: Monocyte cell adhesion induced by a human aminoacyltRNA synthetase. J Leukoc Biol. 2002;71:223-230.
17. Kim MJ, Park BJ, Kang YS, Kim HJ, Park JH, Kang JW, Lee SW, Han JM, Lee HW, and Kim S: Downregulation of FUSEbinding protein and c-myc by tRNA synthetase cofactor p38 is required for lung cell differentiation. Nat Genet. 2003; 34:330-336.
18. Han JM, Park BJ, Park SG, Oh YS, Choi SJ, Lee SW, Hwang SK, Chang SH, Cho MH, and Kim S: AIMP2/p38, the scaffold for the multi-tRNA synthetase complex, responds to genotoxic stresses via p53. Proc Natl Acad Sci USA. 2008; 105:11206-11211.
19. Kim S: Aimp2-dx2 and its uses. Korean Patent Application. 2004, 2005; 10-2004-0097164, 10-2005-39073.
20. Hwang SK, Kwon JT, Park SJ, Chang SH, Lee ES, Chung YS, Beck GR Jr, Lee KH, Piao L, Park J, and Cho MH: Lentivirusmediated carboxyl-terminal modulator protein gene transfection via aerosol in lungs of K-ras null mice. Gene Ther. 2007;14:1721-1730.
21. Iruela-Arispe ML, and Dvorak HF: Angiogenesis: a dynamic balance of stimulators and inhibitors. Thromb Haemost. 1997;78:672-677.
22. Cusack S: Aminoacyl-tRNA synthetases. Curr Opin Struct Biol. 1997;7:881-889.
23. Choi JW, Um JY, Kundu JK, Surh YJ, and Kim S: Multidirectional tumor-suppressive activity of AIMP2/p38 and the enhanced susceptibility of AIMP2 heterozygous mice to carcinogenesis. Carcinogenesis. 2009;30:1638-1644.
24. Choi JW, Kim DG, Lee AE, Kim HR, Lee JY, Kwon NH, Shin YK, Hwang SK, Chang SH, Cho MH, Choi YL, Kim J, Oh SH, Kim B, Kim SY, Jeon HS, Park JY, Kang HP, Park BJ, Han JM, and Kim S: Cancer-associated splicing variant of tumor suppressor AIMP2/p38: pathological implication in tumorigenesis. PLoS Genet. 2011;7:e1001351.
25. Chen J, Somanath PR, Razorenova O, Chen WS, Hay N, Bornstein P, and Byzova TV: Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat Med. 2005;11:1188-1196.
26. Pullen N, Dennis PB, Andjelkovic M, Dufner A, Kozma SC, Hemmings BA, and Thomas G: Phosphorylation and activation of p70s6k by PDK1. Science. 1998;279:707-710.
27. Bjornsti MA, and Houghton PJ: The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004;4:335-348.
28. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, and Blenis J: mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol. 2004;24: 200-216.
29. Martin ME, Perez MI, Redondo C, Alvarez MI, Salinas M, and Fando JL: 4E binding protein 1 expression is inversely correlated to the progression of gastrointestinal cancers. Int J Biochem Cell Biol. 2000;32:633-642.
30. McClusky DR, Chu Q, Yu H, Debenedetti A, Johnson LW, Meschonat C, Turnage R, McDonald JC, Abreo F, and Li BD: A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer. Ann Surg. 2005;242:584-592.
31. Walsh D, Meleady P, Power B, Morley SJ, and Clynes M: Increased levels of the translation initiation factor eIF4E in differentiating epithelial lung tumor cell lines. Differentiation. 2003;71:126-134.